You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
STTR Phase I:Integrated Chemical and Supercritical Carbon Dioxide (CO2) Energy Storage
SBC: Solve Technology and Research, Inc. Topic: ENThe broader impact/ commercial potential of this Small Business Technology Transfer (STTR) project to address a technological innovation in energy storage. Energy storage is a critical technology for the energy utility industries offering more reliable and affordable energy supply, a cleaner environment, and stronger energy infrastructure. Specific advantages of energy storage include a robust ene ...
STTR Phase I 2023 National Science Foundation -
STTR Phase II:Nanomaterial-based Residual Active Disinfectant for Decreasing Surface Acquired Infections
SBC: Heliobiosys, Inc Topic: CTThe broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is the development of a nanotechnology-based coating to combat the rise in Healthcare Acquired Infections (HAIs). HAIs spread in hospitals through healthcare workers’ hands and exposed surfaces. The coating technology developed through this project will disinfect surfaces contaminated with ...
STTR Phase II 2023 National Science Foundation -
STTR Phase I:Steroid-eluting thread for the treatment of rhinitis
SBC: SIMPLYBREATHE L.L.C. Topic: MDThe broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the ca ...
STTR Phase I 2023 National Science Foundation -
STTR Phase I: Patient-Specific System for Early Detection and Identification of Epileptic Seizures
SBC: AI-NEOTECH LLC Topic: BTThe broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to provide epileptic patients, and their caregivers a smart system that can predict seizures before they occur.There are more than 3 million adults and 1 million children in the US, and more than 50 million people worldwide, suffering from epilepsy.Repeated and unpredictable seizures signif ...
STTR Phase I 2023 National Science Foundation -
STTR Phase II: Scalable Thermochemical Conversion of Carbon Dioxide to Commodity Chemical Intermediates
SBC: CL CHEMICAL COMPANY Topic: CTThe broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is to advance dynamic chemical reactor systems that repurposes waste gases (primarily carbon dioxide (CO2)) for use as fuels and as chemicals. This effort can have substantial commercial and market impacts as its output is compatible with existing infrastructure. This project leverages signif ...
STTR Phase II 2023 National Science Foundation -
SBIR Phase II:A Software Platform for Assessment of Untrusted Electronics
SBC: SILICON ASSURANCE LLC Topic: SThe broader/commercial impact of this Small Business Innovation Research (SBIR) Phase II project is to address hardware security and trust issues that are threatening the semiconductor supply chain. Various threats exist from the design stage till the end of the life of chips, such as malicious logic insertion, intellectual property (IP) theft, reverse engineering, backdoor insertion, and informat ...
STTR Phase II 2023 National Science Foundation -
An intramammary subunit vaccine to prevent Staphylococcus aureus bovine mastitis
SBC: Pentamer Biologics LLC Topic: 83Mastitis or inflammation of the udder is considered the most economically significant diseaseaffecting dairy cattle worldwide; costing the industry an estimated $2 billion a year. The bacteriumStaphylococcus aureus is a main cause of mastitis that can establish subclinical infection and resultin long term reductions in milk yield. Our innovation is a subunit vaccine that can be administeredto muco ...
STTR Phase I 2023 Department of Agriculture -
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Assessment of Deep Learning Classification Methods for Parkinsonism
SBC: AUTOMATED IMAGING DIAGNOSTICS LLC Topic: 108SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MT-125 for the Therapeutic Treatment of Glioblastoma
SBC: MYOSIN THERAPEUTICS INC. Topic: 102PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health